USPTO serial 79207192
HUMABFC
Reviewed by CopyMark Law Group
Reg. 5510331Status 709
- Filing date
- Status date
- Registration date
- Jul 10, 2018
- Examiner
- MARCY, AMY ALFIERI
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HUMABFC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
FR
Other trademarks owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
FR
Other trademarks owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
FR
Other trademarks owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monte L. Falcoff/Jessica S. Sachs
Monte L. Falcoff/Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.5445 Corporate DriveSuite 200Troy, MI 48098Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
- Other trademarks owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
- Other trademarks owned by LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named HUMABFC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 3, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 14, 2026 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 21, 2026 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Apr 21, 2026 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Sep 24, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 24, 2025 | C71T | CANCELLED SECTION 71 | — |
| May 4, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 10, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Apr 9, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 6, 2021 | CORN | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Apr 3, 2021 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Mar 5, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 21, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 16, 2018 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Oct 16, 2018 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Oct 10, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 10, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 24, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 24, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 20, 2018 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 4, 2018 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 4, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 4, 2018 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Mar 17, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 6, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 5, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 5, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 11, 2017 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 11, 2017 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 11, 2017 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 14, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 14, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 3, 2017 | ALIE | ASSIGNED TO LIE | — |
| Oct 24, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 10, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 23, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 23, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 17, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 14, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 13, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 13, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 11, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |